References
- Barnett G, Williams AC. Re: cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. J Med Econ [Epub ahead of Print].
- Valldeoriola F. Cost and efficacy of therapies for advanced Parkinson's Disease. Barcelona, Spain: Institut de Neurociències, Hospital Clínic, Universitat de Barcelona, 2011
- Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Med Econ 2013;16:191-201
- Eggington S, Valldeoriola F, Chaudhuri KR, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s Disease. J Neurol 2014;261:106-16
- Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord 2013;28:763-71
- Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkin-son's disease: A cost-effectiveness analysis. Neurology 2001;57:663
- Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Par-kinson's disease patients with wearing-off. Curr Med Res Opin 2005;21:1005-14
- Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New Engl J Med 2006;355:896-908
- Weaver F, Follett K, Stern M, et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson disease: a randomised controlled trial. JAMA 2009;301:63-73
- De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-3
- Ceballos-Baumann A. Continuous subcutaneous infusion therapy with the Apo-morphinePump. Akt Neurol 2011;38:S17-S26
- Pollak P, Champay AS, Gaio JM, et al. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990;146:116-22
- Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43
- Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7
- Chaudhuri KR, Critchley P, Abbott RJ, et al. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988;2:1260
- Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative long-term study. Adv Neurol 1993;60:653-5
- Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in pa-tients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
- García Ruiz PJ, Ignacio AS, Pensado BA, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's Disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6
- Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Medl Econ 2013;16:191-201